Pediatric Multiple Sclerosis Medication

Updated: Jan 03, 2022
  • Author: Alice K Rutatangwa, DO, MSc; Chief Editor: Stephen L Nelson, Jr, MD, PhD, FAACPDM, FAAN, FAAP, FANA  more...
  • Print
Medication

Medication Summary

Fingolimod is the first drug approved for multiple sclerosis (MS) treatment in children.

Published studies have provided information for off-label use of beta interferons. [48, 47, 48]

Next:

Sphingosine 1-Phosphate Receptor Modulators

Class Summary

These agents may block lymphocyte capacity to egress from lymph nodes, and thereby reduce lymphocyte migration into the CNS.

Fingolimod (Gilenya, Tascenso ODT)

Fingolimod is the first drug approved for children aged ≥10 years with relapsing forms of MS. The mechanism of action for MS is unknown. It may involve a reduction of lymphocyte migration into the central nervous system. Fingolimod is available as capsules and oral disintegrating tablets.

Previous
Next:

Immunomodulators

Class Summary

Immunomodulators or receptor modulators are indicated for the treatment of adults with relapsing forms of MS. They help to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.

Interferon beta-1b (Betaseron, Extavia)

Immunomodulators or receptor modulators are indicated for the treatment of adults with relapsing forms of MS. Shown to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.

Interferon beta 1a (Avonex, Rebif)

The exact mechanism by which interferon beta-1a exerts its effects is not fully defined. Interferon beta inhibits the expression of proinflammatory cytokines, including interferon gamma, which is believed to be a major factor responsible for triggering the autoimmune reaction leading to MS.

Previous